Trial Profile
A Phase II Study of Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary) ; Pembrolizumab (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 18 May 2020 Planned End Date changed from 31 Aug 2020 to 31 Dec 2020.
- 18 May 2020 Planned primary completion date changed from 28 Feb 2020 to 28 Dec 2020.
- 18 May 2020 Status changed from recruiting to active, no longer recruiting.